The geography of drug development is rarely a level playing field, and for Soleno Therapeutics, the map has recently contracted. The California-based biotech, which has spent years developing a treatment for rare genetic obesity, has agreed to be acquired by Neurocrine Biosciences. But the deal lacks the typical premium of a high-growth exit; instead, Soleno is selling at a discount, a move necessitated by a darkening regulatory forecast in Europe.
The crux of the devaluation lies in the dwindling prospects for Soleno’s lead candidate to clear European regulatory hurdles. While the U.S. market often provides the primary engine for biotech valuations, the inability to secure a foothold in the European Union can fundamentally break the financial model of a mid-sized firm. For Soleno, the realization that a European approval was increasingly unlikely stripped the company of its leverage, turning a potential expansion into a search for a safe harbor.
This acquisition underscores the precarious nature of the "single-asset" biotech firm. When the path to global market access is obstructed, the capital required to sustain independent operations often becomes untenable. Neurocrine, with its broader portfolio and deeper pockets, may yet find a way to navigate these complexities, but for Soleno, the sale marks a quiet conclusion to a once-ambitious independent run.
With reporting from Endpoints News.
Source · Endpoints News
